Treatment of osteoporosis: why, whom, when and how to treat

Ego Seeman and John A Eisman
Med J Aust 2004; 181 (5): . || doi: 10.5694/j.1326-5377.2004.tb06283.x
Published online: 6 September 2004

Ego Seeman,* John A Eisman†

  • Ego Seeman2
  • John A Eisman2

  • 1 Austin Hospital, Studley Road, Heidelberg, VIC 3084.
  • 2 and Director, Bone and Mineral Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, NSW.


Competing interests:

E S has been paid to sit on medical advisory boards for Aventis, Eli Lilly, and Merck Sharp & Dohme; J A E has been a paid consultant for Aventis, Eli Lilly, Merck Sharp & Dohme, NPS (USA), Organon, Roche and Servier.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.